<DOC>
	<DOCNO>NCT00005802</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill leukemia cell . Treating donor white blood cell interleukin-2 laboratory may help kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose interleukin-2 give chemotherapy donor white blood cell see well work treat patient acute myeloid leukemia acute lymphoid leukemia .</brief_summary>
	<brief_title>Chemotherapy Followed Donor White Blood Cells Plus Interleukin-2 Treating Patients With Acute Myeloid Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose interleukin-2 follow donor lymphocyte infusion chemotherapy patient relapse acute myeloid lymphoid leukemia allogeneic peripheral blood stem cell transplantation . - Determine toxicity efficacy regimen patient . OUTLINE : This dose escalation study interleukin-2 ( IL-2 ) . Patients stratify accord disease status chemotherapy ( acute myeloid leukemia ( AML ) complete remission ( CR ) v acute lymphoid leukemia ( ALL ) AML CR ) . Patients receive one three induction chemotherapy regimen , depend type leukemia , prior treatment , response . - Regimen 1 : Patients receive high dose cytarabine IV 2 hour twice day day 1 , 3 , 5 . - Regimen 2 : Patients receive mitoxantrone IV 15 minute etoposide IV 30 minute day 1-5 . - Regimen 3 : Patients receive fludarabine IV 30 minute day 1-5 , cytarabine IV 2 hour day 1-4 , filgrastim ( G-CSF ) subcutaneously begin day 1 continue blood count recover . Patients extramedullary relapse receive local radiotherapy . Patients ALL CNS relapse receive intrathecal methotrexate without hydrocortisone cytarabine . Patients receive one donor lymphocyte infusion IV 15-30 minute within 28-60 day start chemotherapy . On day , IL-2 IV administer 24 hour 5 day . After 2 day rest , IL-2 administer continuously 10 day . Cohorts 5 patient receive escalate dos IL-2 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 5 patient experience dose limit toxicity . Up 40 patient treated MTD . Patients follow monthly 3 month , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 11-15 patient per year accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Relapsed acute myeloid leukemia acute lymphoid leukemia allogeneic peripheral blood stem cell transplantation ( PBSCT ) , document 1 following : Morphologic relapse define 1 following : Peripheral blast absence growth factor therapy Bone marrow blast great 5 % nucleated cell Extramedullary ( CNS , testicular , sit ) Flow cytometric relapse define appearance peripheral blood bone marrow cell abnormal immunophenotype consistent leukemia recurrence note pretransplant Cytogenetic relapse define : Appearance 1 metaphase bone marrow peripheral blood cell nonconstitutional cytogenetic abnormality note least 1 cytogenetic study perform prior transplant OR New abnormality know associated leukemia Allogeneic PBSCT relate ( HLA identical 1 antigen mismatch ) OR unrelated ( match ) donor Must achieve complete remission PBSCT Current donor must prior donor Age 10 PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 02 Life expectancy : At least 3 month Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No congestive heart failure require diuretic No uncontrolled arrhythmia Pulmonary : No pulmonary dysfunction require oxygen therapy No pneumonia severe obstruction FEV_1 least 50 % predict OR great 50 % decline baseline No severe restrictive lung disease ( total lung capacity le 60 % 50 % decline baseline ) due leukemia Other : No sepsis , aspergillosis , active infection PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent cyclosporine tacrolimus induction chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>